Key facts
- This page summarizes Alfonso G. Zulueta's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Jan 2024, 19:55.
Alfonso G. Zulueta - 21 Dec 2023 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- Director
- Issuer ticker
- CLDI
- Reported as of
- 21 Dec 2023
- Net transaction value
- +$10,159
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2024, 19:55:27 UTC
- Prior SEC filing
- 06 Nov 2023
- Next SEC filing
- 08 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendy Pizarro, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Alfonso G. Zulueta filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 04 Jan 2024.
Change
- Previous filing in this sequence was filed on 06 Nov 2023.
- Current net transaction value: +$10,159.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDI
transaction
Common Stock
Award
- Transaction value
- $10,159
- Shares
- +5,644
- Change %
- +4.4%
- Price
- $1.80
- Shares after
- 133,301
- Date
- 21 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Alfonso G. Zulueta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Represents a grant of restricted stock units ("RSUs") subject to the conditions of the Restricted Stock Unit Award Agreement pursuant to the Issuer's 2023 Plan. Each RSU represents a right to receive one share of the Company's common stock upon vesting. The number of RSUs to be issued will equal to the amount due to the director for Board fees divided by the closing price for a share of the Issuer's common stock. The RSUs were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. The shares of common stock underlying the RSUs immediately vested on the grant date. As previously reported, Mr. Alfonso resigned as a director on November 29, 2023.